Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies
Pediatric Blood & Cancer · 2025-09 · 72 (9)
DOI: 10.1002/pbc.31885 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 02.07.2025. Verfasst von Samanta Catueno und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Ataxia Telangiectasia, Lymphoma, Large B-Cell, Diffuse, Molecular Targeted Therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Octapharma (travel, accommodations, research), Leukemia Lymphoma Society (research funding), Kura Oncology (research funding).
Abstract (Originalsprache)
Patients with ataxia–telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B‐cell lymphoma, alemtuzumab for T‐cell prolymphocytic leukemia, and venetoclax for early T‐cell precursor acute lymphoblastic leukemia. These cases highlight the potential of targeted agents to improve outcomes while minimizing toxicity. Our findings underscore the need for further research to optimize treatment approaches in this high‐risk population, offering novel insights into personalized therapy for patients with AT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Samanta Catueno, Miriam B Garcia, David McCall, Michael Roth, Amber Gibson
Förderung
- Octapharma (travel, accommodations, research)
- Leukemia Lymphoma Society (research funding)
- Kura Oncology (research funding)
- Syndax Pharmaceuticals (travel, accommodations, research funding)
Zitieren
APA
Catueno, S., Ramakrishnan, R., Elitzur, S., Garcia, M. B., McCall, D., Nunez, C., Roth, M., Ferrajoli, A., Cuglievan, B., & Gibson, A. (2025). Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies. Pediatric Blood & Cancer, 72(9). https://doi.org/10.1002/pbc.31885
Vancouver
Catueno S, Ramakrishnan R, Elitzur S, Garcia MB, McCall D, Nunez C, et al. Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies. Pediatric Blood & Cancer. 2025;72(9). doi:10.1002/pbc.31885
BibTeX
@article{Catueno2025,
author = {Catueno, Samanta and Ramakrishnan, Ramya and Elitzur, Sarah and Garcia, Miriam B and McCall, David and Nunez, Cesar and Roth, Michael and Ferrajoli, Alessandra and Cuglievan, Branko and Gibson, Amber},
title = {Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies},
journal = {Pediatric Blood & Cancer},
year = {2025},
volume = {72},
number = {9},
doi = {10.1002/pbc.31885}
}
EUVIMED